The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England

Department of Haematological Medicine, Kings HealthCare NHS Trust, Denmark Hill, London, SE5 9RS, UK.

There is a paucity of epidemiological data on chronic myeloproliferative disorders and myelodysplastic syndromes (MDS), while subtypes of acute myeloid leukemia (AML) are rarely defined. We identified 2,112 adult myeloid malignancies in the South Thames area between 1999 and 2000. The incidence (European standard population) of AML was 3.00/100,000, that of MDS 3.47/100,000, chronic myelomonocytic leukemia (CMML) 0.46/100,000, idiopathic myelofibrosis (IMF) 0.37/100,000, polycythemia vera (PV) 1.08/100,000, primary thrombocythemia (PT) 1.65/100,000 and chronic myeloid leukemia (CML) 1.09/100,000. The 3-year survival for AML was 15%, MDS 45%, CMML 29%, IMF 48%, PV 80%, PT 81% and CML 50% We believe this study reflects the true incidence and outcome of myeloid malignancies in South East England.

This article has been cited by other articles:

				D. T. Bowen, P. Fenaux, E. Hellstrom-Lindberg, and T. de Witte Time-Dependent Prognostic Scoring System for Myelodysplastic Syndromes Has Significant Limitations That May Influence Its Reproducibility and Practical Application J. Clin. Oncol., March 1, 2008; 26(7): 1180 - 1180. [Full Text] [PDF]